Table 1.
Clinical trials on Everolimus in neuroendocrine tumors (NET).
| Title (Phase) | Year | Population | Treatments | PFS (HR) | Remarks |
|---|---|---|---|---|---|
| RADIANT-1 (II) | 2010 | 160 panNET | (I) Everolimus (II) Everolimus + Octreotide LAR |
9.7 16.7 |
No comparison between strata |
| RADIANT-2 (III) | 2011 | 429 mixed (carcinoid syndrome) | Everolimus + Octreotide LAR vs. pbo + Octrotide LAR | 16.4 vs. 11.3 (HR: 0.77) |
Not significant by central radiology analysis |
| RADIANT-3 (III) | 2011 | 410 panNET | Everolimus vs. pbo | 11 vs. 4.6 (HR: 0.35) |
40% concomitant SSA |
| RADIANT-4 (III) | 2016 | 302 mixed non-panceratic | Everolimus vs. pbo | 11 vs. 3.9 (HR: 0.48) |
Concomitant SSA not allowed |
| LUNA trial (II) | 2017 | 124 thoracic (lung thymic) | Pasireotide Everolimus Everolimus + Pasireotide |
8.5 12.5 11.8 |
No comparison among arms |
Year: year of publication; pbo: placebo; SSA: somatostatin analog; PFS expressed in months.